Compare VanEck Junior Gold Miners (GDXJ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Tango Therapeutics Inc. — how do they compare? VanEck Junior Gold Miners trades at $106.1 (market cap $8.21B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: VanEck Junior Gold Miners is far larger — about 2.2× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Tango Therapeutics Inc. for 0 Days on average.
| GDXJ | TNGX | |
|---|---|---|
Market Cap | $8.21B | $3.75B |
Volume | 2,596,073 | 9,619,106 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $32.90 |
52-Week Low | $87.56 | $7.50 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.63, down 2.03% on the day amid a bearish technical signal from moving averages. Recent news highlights multiple junior mining companies being added to the ETF's index, potentially increasing its diversification and investor interest. Key technical indicators show mixed signals, with oscillators neutral but moving averages and overall signal leaning bearish.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Investment opportunities include exposure to gold's potential upside through leveraged junior miners, but risks involve sector-specific volatility, operational challenges of small-cap miners, and broader market sentiment shifts affecting gold prices.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
